Cargando…

Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation

Detalles Bibliográficos
Autores principales:	Lin, Chengjie, Li, Ting, Wang, Yan, Lai, Shihui, Huang, Yue, Guo, Zhenyun, Zhang, Xiang, Weng, Shangeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390565/ https://www.ncbi.nlm.nih.gov/pubmed/37524717 http://dx.doi.org/10.1038/s41419-023-05939-1

Ejemplares similares

METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
por: Lin, Chengjie, et al.
Publicado: (2023)

METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification
por: Guo, Zhenyun, et al.
Publicado: (2022)

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma
por: Tu, Qiu, et al.
Publicado: (2022)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway
por: Lin, Chengjie, et al.
Publicado: (2022)

DDX5/METTL3-METTL14/YTHDF2 Axis Regulates Replication of Influenza A Virus
por: Zhao, Lingcai, et al.
Publicado: (2022)

DDX17 promotes the growth and metastasis of lung adenocarcinoma
por: Liu, Xiaohui, et al.
Publicado: (2022)

The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas
por: Liang, Shan, et al.
Publicado: (2015)

Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma
por: Wu, Hongjin, et al.
Publicado: (2021)

N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer
por: Lai, Shihui, et al.
Publicado: (2022)

A METTL3-METTL14 complex mediates mammalian nuclear RNA N(6)-adenosine methylation
por: Liu, Jianzhao, et al.
Publicado: (2013)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023)

METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma
por: Lu, Liting, et al.
Publicado: (2022)

Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis
por: Ramaswamy, Anant, et al.
Publicado: (2023)

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Leung, Lisa, et al.
Publicado: (2012)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Upregulation of METTL14 mediates the elevation of PERP mRNA N(6) adenosine methylation promoting the growth and metastasis of pancreatic cancer
por: Wang, Min, et al.
Publicado: (2020)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine
por: Fuller, Ryan N, et al.
Publicado: (2022)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
por: Rimmer, Ella, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460
por: Zhu, Xiao‐Xu, et al.
Publicado: (2022)

The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
por: Hii, Ling-Wei, et al.
Publicado: (2019)

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
por: Kan, Shin, et al.
Publicado: (2015)

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Mikamori, Manabu, et al.
Publicado: (2017)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression
por: Liu, Chengmin, et al.
Publicado: (2023)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model
por: Donohue, Elizabeth, et al.
Publicado: (2013)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qiqvv54o5nd2h70peo97bis2ju